Home Property & Construction First homes sell at final phase of flagship £45 million housing development

First homes sell at final phase of flagship £45 million housing development

Gemma Cammish, Darren Pelusi, Karen Howard, Tony Hoare, and Victoria Smith

The first homes are selling at the final phase of Beyond Housing’s flagship Mill Meadows development in Filey.

Marketed under tradename Viola Homes, the 112 homes in the third phase of the 296-home site, are all for open market sale. This is a first for Beyond Housing, which delivered the earlier phases of the development to include affordable properties for both rent and shared ownership. The third phase will also deliver a shop unit.

The homes in the final phase at Mill Meadows, will be exclusively marketed through Viola Homes, alongside Beyond Housing’s other new build homes for open market sale, shared ownership and rent to buy across Teesside and North Yorkshire.

The recent launch of the show homes at Mill Meadows marks the first major milestone for Viola Homes since its launch in October 2021.


The new, family-friendly homes at Mill Meadows consist of two, three, four and five-bedroom houses and bungalows, and will be built alongside new play areas, public open space, highways and other infrastructure. The first homes released for sale are reserved, with high customer interest in further releases.

Mill Meadows is situated at the coastal town of Filey, in North Yorkshire between Scarborough and Bridlington. This final phase of the £45million development, will run for three years, with handover of the final homes scheduled for February 2024.

Karen Howard, Development, Sales and Performance Manager at Beyond Housing, said: “Viola Homes is a welcome addition to the Beyond Housing brand. As a company, we are committed to delivering quality housing in sustainable communities, where it is needed.
“Mill Meadows is a fantastic development, which, over several years, has brought a mix of tenures to the town of Filey, with the third and final phase of the scheme proving every bit as popular as the previous two.”